ClinicalTrials.gg
CompletedNCT00757562Updated Aug 15, 2024

Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)

A Phase 3 interventional study of desloratadine and Placebo in Chronic Idiopathic Urticaria and Atopy, sponsored by Organon and Co. Completed. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 10 months after the study started (first participant enrolled Nov 2002, registered Sep 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
2 Years to 12 Years
Sex
All
01

Study summary

This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine.

02

Conditions studied

  • Chronic Idiopathic Urticaria
  • Atopy

Browse trials for

03

In context

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

This study's enrollment of 97 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.

Browse Chronic Urticaria studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must:

  • have been previously identified through the previous study P03031 to be atopic or with chronic idiopathic urticaria and be a poor metabolizer of desloratadine.
  • have clinical laboratory tests within normal limits.
  • be in good health, free of any disease that could interfere with the study.
  • normal 12-lead

Exclusion criteria

Exclusion Criteria:

Subjects who:

  • have a history of any local or systemic infectious disease within 4 weeks prior to treatment.
  • have taken any medication that is restricted by the protocol or failed to satisfy washout requirements.
  • are allergic to desloratadine.
  • have used a loratadine- or desloratadine-containing product within the past 30 days.
  • are female and menstruating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    DL

    Desloratadine syrup once daily

    Drug: desloratadine

  • Placebo comparator
    Placebo

    placebo syrup once daily

    Drug: Placebo

Interventions

  • desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.

    Also known as: SCH 034117, Clarinex

  • DrugPlacebo

    placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerance

    Time frame: Weekly throughout the 5-week study (Day 1, Day 8, Day 15, Day 22, Day 29, and Day 36).

Secondary outcomes

  1. Plasma concentration data (of desloratadine to loratadine) prior to administration of desloratadine on Days 15 and Days 36.

    Time frame: Days 15 and Days 36

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2002 to primary completion in Oct 2003, 11 months.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 11 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2008
First posted
Sep 23, 2008
StartActual
Nov 1, 2002
Primary completionActual
Oct 1, 2003
CompletionActual
Oct 1, 2003
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00757562
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 23, 2008
Start date
Nov 1, 2002
Primary completion
Oct 1, 2003
Completion
Oct 1, 2003
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion